⌕
4D Molecular Therapeutics · FDMT · Nasdaq
Tenet 52 · Mixed
Compare
$10.79−4.43%At closeTenet 52 · Mixed
$10.79−0.50 (−4.43%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

4D Molecular Therapeutics (FDMT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is FDMT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 13, 2026 · 20:58 ET
4D Molecular Therapeutics, Inc. (FDMT) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. ( FDMT ) Stifel 2026 Healthcare Conference 2026 November 11, 2026 8:00 AM EST Company Participants Christopher Simms - Chief Commercial & Business Officer Kristian Humer - CFO and Principa…

FDMT −4.4% todayRead at source ↗
● GlobeNewsWireNov 13, 2026 · 16:05 ET
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with pot…

FDMT −4.4% todayRead at source ↗
● Zacks Investment ResearchNov 12, 2026 · 19:06 ET
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Tops Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.01 per share a year ago.…

FDMT −4.4% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 16:05 ET
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, respect…

FDMT −4.4% todayRead at source ↗
● Seeking AlphaNov 11, 2026 · 16:38 ET
4D Molecular Therapeutics, Inc. (FDMT) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript…

FDMT −4.4% todayRead at source ↗
● Defense WorldNov 7, 2026 · 05:32 ET
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are covering the stock, Marketbeat.com reports. One rese…

FDMT −4.4% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 08:00 ET
4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with pot…

FDMT −4.4% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 11:01 ET
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

FDMT −4.4% todayRead at source ↗
● MarketBeatOct 22, 2026 · 07:02 ET
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy

4D Molecular Therapeutics NASDAQ: FDMT used its first Investor Day to outline its development and commercial plans for 4D-150, an investigational intravitreal gene therapy for wet age-related macular degeneration, or wet…

FDMT −4.4% todayRead at source ↗
● Seeking AlphaOct 21, 2026 · 18:24 ET
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript

4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript…

FDMT −4.4% todayRead at source ↗
● Defense WorldOct 21, 2026 · 04:15 ET
Reviewing GeoVax Labs (NASDAQ:GOVX) & 4D Molecular Therapeutics (NASDAQ:FDMT)

GeoVax Labs (NASDAQ: GOVX - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses b…

FDMT −4.4% todayRead at source ↗
● GlobeNewsWireOct 16, 2026 · 16:05 ET
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with pot…

FDMT −4.4% todayRead at source ↗
● Defense WorldOct 13, 2026 · 04:29 ET
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Price Target of $28.90

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) has received an average rating of "Moderate Buy" from the twelve brokerages that are covering the company, MarketBeat Ratings reports. One research analyst…

FDMT −4.4% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 08:00 ET
4DMT to Host Investor Day on October 21, 2026

Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.…

FDMT −4.4% todayRead at source ↗
● Seeking AlphaSep 29, 2026 · 17:27 ET
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway

4D Molecular Therapeutics remains a 'Buy' as its gene therapy 4D-150 advances in phase 3 trials for wet AMD and diabetic macular edema [DME]. Topline data from the pivotal 4FRONT-1 and 4FRONT-2 wet AMD studies are expect…

FDMT −4.4% todayRead at source ↗
● GlobeNewsWireSep 28, 2026 · 08:00 ET
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with po…

FDMT −4.4% todayRead at source ↗
● Defense WorldSep 24, 2026 · 05:09 ET
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the firm's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $13.65,…

FDMT −4.4% todayRead at source ↗
● Defense WorldSep 21, 2026 · 03:59 ET
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.56 Average PT from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One an…

FDMT −4.4% todayRead at source ↗
● Seeking AlphaSep 17, 2026 · 10:48 ET
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript…

FDMT −4.4% todayRead at source ↗
● Seeking AlphaSep 14, 2026 · 22:01 ET
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

FDMT −4.4% todayRead at source ↗
● GlobeNewsWireSep 11, 2026 · 16:05 ET
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with po…

FDMT −4.4% todayRead at source ↗
● GlobeNewsWireAug 25, 2026 · 08:00 ET
4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with pot…

FDMT −4.4% todayRead at source ↗
● Defense WorldAug 25, 2026 · 03:55 ET
4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DE

Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) by 17.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The…

FDMT −4.4% todayRead at source ↗
● Defense WorldAug 24, 2026 · 03:54 ET
Deutsche Bank AG Invests $9.46 Million in 4D Molecular Therapeutics, Inc. $FDMT

Deutsche Bank AG acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired …

FDMT −4.4% todayRead at source ↗
● Defense WorldAug 18, 2026 · 03:45 ET
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High – Time to Buy?

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report)'s share price reached a new 52-week high on Tuesday. The company traded as high as $15.03 and last traded at $14.55, with a volume of 3444983 shares. The s…

FDMT −4.4% todayRead at source ↗

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA24+3.0%
LAW4−8.6%
BAC3−1.3%

Article counts from the last market-wide feed page, across every symbol we track and not just FDMT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.